Biotech entity
Every one of those 1 sits in a single category, funding. Of the tracked stories, 1 of 1 also mention Dr Vivek Bhadri, the most common co-covered peer. The tracked stories average 10 original sources each. Angela de Weger appears in 1 tracked Biotech story from July 11, 2026.
Last mentioned: Jul 11, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, funding. Of the tracked stories, 1 of 1 also mention Dr Vivek Bhadri, the most common co-covered peer. The tracked stories average 10 original sources each. Angela de Weger appears in 1 tracked Biotech story from July 11, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 9 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Angela de Weger. Shared-story counts are live from our verified record — not editorial picks.
With under 1% of cancer research funding, sarcoma presents a high-need, underserved market for biotech and pharma. Orphan drug incentives and emerging targets could unlock significant value in rare cancer therapies.
Source: easternriverinachronicle.com.au · katherinetimes.com.au
Angela de Weger is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
